Baxter International (BAX)
(Delayed Data from NYSE)
$33.30 USD
-0.78 (-2.29%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $33.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth F Momentum B VGM
Brokerage Reports
Baxter International Inc. [BAX]
Reports for Purchase
Showing records 481 - 500 ( 507 total )
Company: Baxter International Inc.
Industry: Medical - Products
5 Key Questions for Management Ahead of Baxter?s October 9th Analyst Meeting
Provider: COLLIERS SECURITIES
Analyst: HUSAIN J
Company: Baxter International Inc.
Industry: Medical - Products
Company: Baxter International Inc.
Industry: Medical - Products
Decent 2Q:12 But Pending HyQ Complete Response Letter and Late 3Q Plasma Plant Shutdown Weighs on Our Mind - Maintain BAX-Neutral
Provider: COLLIERS SECURITIES
Analyst: HUSAIN J
Company: Baxter International Inc.
Industry: Medical - Products
Company: Baxter International Inc.
Industry: Medical - Products
Medical Technology: Thoughts on Our Medical Technology Universe Heading Into the Dog Days of Summer
Provider: COLLIERS SECURITIES
Company: Baxter International Inc.
Industry: Medical - Products
BAX: FDAs BPAC Advisory Panel Meeting in July August is Probably a No Go The Bull and Bear Case for Baxters HyQ
Provider: COLLIERS SECURITIES
Company: Baxter International Inc.
Industry: Medical - Products
Griffin Securities Initiates Coverage of Novelos Therapeutics
Provider: GRIFFIN SECURITIES, INC.
Analyst: MARKEY K
Company: Baxter International Inc.
Industry: Medical - Products
Griffin Securities Initiates Coverage of Novelos Therapeutics
Provider: GRIFFIN SECURITIES, INC.
Analyst: MARKEY K
Company: Baxter International Inc.
Industry: Medical - Products
Company: Baxter International Inc.
Industry: Medical - Products
BAX: Okay 1Q:12 Lots of Moving Parts in 2H:12 with BPAC Meeting, Plant Shutdown, and IVIG Pricing
Provider: COLLIERS SECURITIES
Company: Baxter International Inc.
Industry: Medical - Products
BAX: Keep an Eye on IVIG Backorders, Especially Ahead of LA Plasma Plant Shutdown
Provider: COLLIERS SECURITIES
Company: Baxter International Inc.
Industry: Medical - Products
BAX: HyQvia Long Term Data to be Presented at a Medical Meeting on Monday Afternoon We Like This Product, Raising PT
Provider: COLLIERS SECURITIES
Company: Baxter International Inc.
Industry: Medical - Products
BAX: Inline 4Q:11 But 2012 Guidance Lower Than Expected Were Still Cautious Given Headwinds, Reiterate Neutral
Provider: COLLIERS SECURITIES
Company: Baxter International Inc.
Industry: Medical - Products
Company: Baxter International Inc.
Industry: Medical - Products
BAX: 4Q:11 Preview: Risks With CY12 Guidance and Softer Gross Margins on Plasma Plant Shutdown Take Profits on Positive DSMB Review of Phase III IVIG/Alzheimers
Provider: COLLIERS SECURITIES
Company: Baxter International Inc.
Industry: Medical - Products
Medical Technology: We Believe Recent Pricing Pressures for Infusion Disposables Are Unique to CareFusion
Provider: COLLIERS SECURITIES
Company: Baxter International Inc.
Industry: Medical - Products
BAX: Bioscience Uncertainties, Margin Angst, & Tough Y/Y Comps in CY12 Initiating Coverage of Baxter International (BAX) With a Neutral Rating, PT $55
Provider: COLLIERS SECURITIES
Company: Baxter International Inc.
Industry: Medical - Products
Initiating Coverage With a Neutral Rating, PT $55
Provider: COLLIERS SECURITIES